Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆
Titel:
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study ☆
Auteur:
Lorusso, D. Colombo, N. Dubot, C. Cáceres, M.V. Hasegawa, K. Shapira-Frommer, R. Salman, P. Yañez, E. Gümüş, M. Olivera, M. Samouëlian, V. Castonguay, V. Arkhipov, A. Li, K. Toker, S. Tekin, C. Tewari, K.S. Monk, B.J.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 36 () nr. 1 pagina's 65-75
Jaar:
2025
Inhoud:
Uitgever:
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA., The Author(s)